Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Engineered Salmonella delivers cancer-fighting viruses to deep tumors

Researchers at the University of Massachusetts Amherst have designed non-toxic Salmonella bacteria to deliver viruses that are safe to humans but potent against liver and pancreatic cancer tumors - two cancers with an extremely poor prognosis.

3 Jun 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

STRIDE immunotherapy sets new benchmark for survival in advanced liver cancer

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) has shown that one in five (19.6%) participants treated with STRIDE (Single Tremelimumab Regular Interval Durvalumab) a combination of two immunotherapies, remained alive after five years of follow-up versus one in 10 (9.4%) participants treated with sorafenib, a standard treatment for uHCC when the study was designed.

23 Jul 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and time-to-progression in patients with locally advanced hepatocellular carcinoma (HCC) when compared to sorafenib alone.

20 Dec 2024

Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide.

8 Nov 2024

New perspectives on targeting BRAF alterations in cancer

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions."

12 Aug 2024

Fibrinogen-like protein 1 plays dual role in liver regeneration and hepatocellular carcinoma recurrence

Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits a dismal five-year survival rate of only 18%.

2 Jul 2024

New insights into signaling pathways and resistance mechanisms in colorectal cancer

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The complexity of its pathogenesis, involving genetic mutations, dysregulated signaling pathways, and compromised immune surveillance, presents significant challenges for effective treatment.

21 Jun 2024

Identifying immunotherapy resistance in liver cancer linked to steatotic disease

A research team of Canadian and French scientists, led by INRS professor Maya Saleh, has been investigating immunotherapy resistance in certain patients with hepatocellular carcinoma (HCC) associated with steatotic liver disease.

14 Feb 2024

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

The immune-modulatory effect of lenvatinib investigated in new study

Researchers explore the effect of lenvatinib treatment on patients with advanced thyroid cancer.

9 Aug 2023

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine

A recent study elucidated the molecular mechanisms of drug-induced regulation of growth differentiation factor 15 (GDF15).

1 Aug 2023

Sorafenib News and Research

Tumor environments sculpt diverse natural killer cells for cancer therapies

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

Engineered Salmonella delivers cancer-fighting viruses to deep tumors

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

Genetic and cellular mechanisms underlying steatotic liver disease

STRIDE immunotherapy sets new benchmark for survival in advanced liver cancer

Advancing precision oncology in intrahepatic cholangiocarcinoma

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

New perspectives on targeting BRAF alterations in cancer

Fibrinogen-like protein 1 plays dual role in liver regeneration and hepatocellular carcinoma recurrence

New insights into signaling pathways and resistance mechanisms in colorectal cancer

Identifying immunotherapy resistance in liver cancer linked to steatotic disease

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

The immune-modulatory effect of lenvatinib investigated in new study

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine

Adolescent and young adult kidney cancer survivors at elevated risk for heart problems

Nirogacestat shows promising results in patients with desmoid tumors

Review focuses on the link between the pathogenesis and management of hepatocellular carcinoma

Combination of radiation and systemic therapy can prolong survival for advanced liver cancer patients

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News